CD274 and non-small cell lung carcinoma: Across the various clinical outcomes analyzed, pembrolizumab + chemotherapy appears to have a greater clinical benefit relative to nivolumab + ipilimumab in patients with recurrent/metastatic NSCLC with PD-L1 TPS ≥1%.